Evidence map›Paper›PMID 25881031›Full record

ArticleBiomedical engineering online2015

The necessity of identifying the basal glucose set-point in the IVGTT for patients with Type 2 Diabetes.

Nor Azlan Othman, Paul D Docherty, Jeremy D Krebs, Damon A Bell, J Geoffrey Chase

Open access · goldAbstract read
In one paragraph

Article in Biomedical engineering online, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Nor Azlan OthmanDepartment of Mechanical Engineering, Centre for Bio-Engineering, University of Canterbury, Private Bag 4800, Christchurch, 8054, New Zealand. azlan.othman@pg.canterbury.ac.nz.
Paul D DochertyDepartment of Mechanical Engineering, Centre for Bio-Engineering, University of Canterbury, Private Bag 4800, Christchurch, 8054, New Zealand. paul.docherty@canterbury.ac.nz.
Jeremy D KrebsDepartment of Medicine, University of Otago, Wellington, 6242, New Zealand. Jeremy.Krebs@ccdhb.org.nz.
Damon A BellSchool of Medicine and Pharmacology Royal Perth Hospital Unit, The University of Western Australia, Perth, Western Australia, 6009, Australia. damon.bell@uwa.edu.au.
J Geoffrey ChaseDepartment of Mechanical Engineering, Centre for Bio-Engineering, University of Canterbury, Private Bag 4800, Christchurch, 8054, New Zealand. geoff.chase@canterbury.ac.nz.
University of Canterbury · NZUniversity of Otago · NZUniversity of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe model-based dynamic insulin sensitivity and secretion test (DISST) uses fasting glucose (G 0 ) as the basal glucose (G B ) concentration when assessing insulin sensitivity (SI). However, this model was developed in a healthy, normoglycaemic cohort. We sought to determine the suitability the DISST model has for individuals with established type 2 diabetes (T2D).

methods14 participants with established T2D were recruited to take part in a dietary intervention study. Insulin-modified intravenous glucose tolerance tests (IM-IVGTT) were undertaken at week 0, 12 and 24 and were used with DISST model to identify G B . A total of 36 tests were conducted across 12 participants throughout the study. Measured G 0 and identified G B values were compared using a Kolmogorov-Smirnov (KS) and signed rank (RS) test for the cohort.

resultsThere were significant differences between the G 0 and identified G B values in this cohort (prs and pks < 0.0001), although both values were well correlated (R = 0.70). The residual plot demonstrates that the modified model captures the behaviour of the participants more accurately than the original model.

conclusionsThis analysis has shown that G B is an important variable for modelling the glycaemic behaviour in T2D. These findings suggest that the original DISST model, while appropriate for normoglycaemic cohorts, needs to model basal glucose level as a variable for assessing individuals with established T2D.

Indexed as

Computer SimulationGlucose Tolerance TestModels, BiologicalAdultAgedBlood GlucoseDiabetes Mellitus, Type 2Dose-Response Relationship, DrugFastingFemaleGlucoseHumansInfusions, IntravenousInsulinInsulin ResistanceInsulin SecretionBlood GlucoseGlucoseInsulin

Identifiers

PMID25881031
PMCPMC4350631
OpenAlexW2145148427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.